Medical sales reps have long had a close relationship with physicians, providing services as a surgical consultant as well as a medtech dealer, but that dynamic may be about to change in a big way.
Trends
Medtech trends: The most talked about device makers in August 2014
Hip surgery costs less than conservative care for fractures, ortho docs say
Hip surgeries are likely to become increasingly popular as the U.S. population ages, representing a significant cost burden for the healthcare system, but orthopedic surgeons say the procedure ultimately saves tens of thousands of dollars per patient.
Funding: Medtech VC jumps in Q2, but not for early-stage companies
Life science venture capital funding saw a major boost in the 2nd quarter as public markets smiled on biotech companies, but medical device makers saw a significant boost of their own – as long as they weren’t early-stage firms.
Are device makers falling behind in the digital revolution?
The healthcare space is getting a major influx of digital innovation, but much of it’s coming from outside the traditional parameters of the industry.
Medtronic’s Ishrak completes the ‘Ice Bucket Challenge’ for ALS research (video)
Report: Medtech jobs grew steadily in 2013
Last year may not have been a blockbuster one for medical device makers, but the industry posted steady gains in jobs, according to a new report from EP Vantage.
The analysis of nearly 100 small and large medtech companies found that jobs increased, on average, across the board. A closer look at the top 15 device makers found that jobs increased 6% overall and only 3 of the titans reduced their total headcount during the year, 2 of them by spinning out their pharma divisions.
Medtech trends: The most talked about device makers in July 2014
More mega-merger talk from medtech giants | MassDevice.com On Call
MASSDEVICE ON CALL — More medical device giants offered their 2¢ on high-dollar mega-mergers, joining other companies in saying that they aren’t planning any billion-dollar buys just yet.
Report: Medtech M&A exits don’t hinge on FDA approval
The funding environment for medical device startups isn’t a pretty scene, but there is a ray of sunshine through the gloom: lack of FDA approval is no longer a deal-breaker for a big exit.
In 2013 a few medtech companies managed "big exit M&A" deals (those worth $50 million or more) without having reached the FDA’s brass ring, according to a new report from Silicon Valley Bank.